Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Pablo Tebas
Are screening periods in ART-naive trials justified in the era of rapid ART?
Get full text access Log in, subscribe or purchase for full access. References 1. Panel on Antiretroviral Guidelines for Adults and Adolescents Guidelines for the use of antiretroviral agents in adults and adolescents with HIV Department of Health and Human Services, 2025 2. Gandhi, RT ∙ Landovitz, RJ ∙ Sax, PE ∙ et al. Antiretroviral drugs for treatment and prevention of HIV in Adults: 2024 recommendations of the International Antiviral Society-USA Panel JAMA. 2025; 333:609-628 3.
Safety and pharmacokinetics of SARS-CoV-2 DNA-encoded monoclonal antibodies in healthy adults: a phase 1 trial - Nature Medicine
Retinol Binding Protein 4 reactivates latent HIV-1 by triggering canonical NF-κB, JAK/STAT5 and JNK signalling - Signal Transduction and Targeted Therapy
Abstract Reactivation of the latent viral reservoirs is crucial for a cure of HIV/AIDS. However, current latency reversing agents are inefficient, and the endogenous factors that have the potential to reactivate HIV in vivo remain poorly understood.
Cognate antigen engagement induces HIV-1 expression in latently infected CD4+ T cells from people on long-term antiretroviral therapy
Keywords HIV-1 persistence HIV-1 latent reservoir latency reversal antigenic stimulation dendritic cells CD4+ T cells cytomegalovirus Introduction Antiretroviral therapy (ART) effectively blocks viral replication, but HIV-1 persists in a small pool of latently infected resting CD4+ T cells harboring inducible, replication-competent proviruses.1,2,3 This reservoir was originally characterized with a quantitative viral outgrowth assay (QVOA) in which resting CD4+ T cells are stimulated with...
Will HIV Break the Heart of Africans?
REFERENCES 1. Roth GA, Mensah GA, Johnson CO, Addolorato G, Ammirati E, Baddour LM, Barengo NC, Beaton AZ, Benjamin EJ, Benziger CP, ; GBD-NHLBI-JACC Global Burden of Cardiovascular Diseases Writing Group. Global burden of cardiovascular diseases and risk factors, 1990-2019: update from the GBD 2019 study.J Am Coll Cardiol. 2020; 76:2982–3021. doi: 10.1016/j.jacc.2020.11.010CrossrefMedlineGoogle Scholar 2. Cohen JC, Boerwinkle E, Mosley TH, Hobbs HH .
CCR5-edited CD4+ T cells augment HIV-specific immunity to enable post-rebound control of HIV replication
Erratum Open Access | 10.1172/JCI181576 Published in Volume 134, Issue 9 on May 1, 2024 J Clin Invest. 2024;134(9):e181576. https://doi.org/10.1172/JCI181576. © 2024 replication This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
SARS-CoV-2 DNA Vaccine INO-4800 Induces Durable Immune Responses Capable of Being Boosted in a Phase 1 Open-Label Trial
Abstract Background Additional SARS-CoV-2 vaccines that are safe and effective as both primary series and booster remain urgently needed to combat the COVID-19 pandemic. Here we describe the safety and durability of the immune response from two doses of a DNA vaccine (INO-4800) targeting the full-length Spike antigen and a subsequent homologous booster dose. Methods INO-4800 was evaluated in 120 healthy participants across three dose groups (0.5 mg, 1.0 mg and 2.0 mg), each stratified by age.
Phase 1 Trial of Cyclosporine for Hospitalized Patients with COVID-19
View ORCID ProfileEmily A. Blumberg, View ORCID ProfilePablo Tebas, Ian Frank, Amy Marshall, Anne Chew, Elizabeth A. Veloso, Alison Carulli, Walter Rogal, Avery L. Gaymon, Aliza H. Schmidt, Tiffany Barnette, Renee Jurek, Hooman Noorchashm, Wei-Ting Hwang, Julia Han Noll, View ORCID ProfileJoseph A. Fraietta, View ORCID ProfileCarl H. June, Elizabeth O.
CCR5-edited CD4+ T cells augment HIV-specific immunity to enable post-rebound control of HIV replication
Abstract Introduction Prolonged HIV-1 infection results in massive CD4+ T cell loss and profound immunodeficiency (1). Even with effective antiretroviral therapy (ART), the resident CD4+ T cell response does not fully recover (2–4). Damage to lymphoid tissue, lack of differentiation to enable improved effector function, and preferential killing of HIV-specific CD4+ T cells all limit the CD4+ T cell response (5).
Safety and immunogenicity of INO-4800 DNA vaccine against SARS-CoV-2: A preliminary report of an open-label, Phase 1 clinical trial
Abstract Background A vaccine against SARS-CoV-2 is of high urgency. Here the safety and immunogenicity induced by a DNA vaccine (INO-4800) targeting the full length spike antigen of SARS-CoV-2 are described. Methods INO-4800 was evaluated in two groups of 20 participants, receiving either 1.0 mg or 2.0 mg of vaccine intradermally followed by CELLECTRA® EP at 0 and 4 weeks.
Safety and Immunogenicity of an Anti–Zika Virus DNA Vaccine | NEJM
33 References 150 Citing Articles Related Articles Abstract Background Although Zika virus (ZIKV) infection is typically self-limiting, other associated complications such as congenital birth defects and the Guillain–Barré syndrome are well described. There are no approved vaccines against ZIKV infection.
Immune plasma for the treatment of severe influenza: an open-label, multicentre, phase 2 randomised study
Respiratory medicine and critical care: a call for papers for ERS
Identification of flu-specific ICOS+CD38+ cTfh after influenza vaccination
The foundation of successful vaccines lies in the ability to prime the immune system to target a specific pathogen. The interaction between follicular helper T cells (Tfh) and B cells within germinal centers is necessary for the production of class-switched, affinity-matured antibodies. However, the size, diversity, and specificity of the T cell receptor (TCR) repertoire of the Tfh during an immune response remains unknown.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Pablo
Contact Pablo, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack